Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 2.6 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), a shelf registration filed Mar 16, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$17.4MCash on Hand
2.6mo Cash Runway
Follow CUE by emailGet an email when CUE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CUE, unsubscribe in one click. Privacy
📣 What CUE Says Is Next
by year-end 2026 · “Company anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026 Financial and Corporate”
Company press release, Aug 14, 2026 · SEC filing
by the end of the year · “We look forward to anticipated CUE-221 Phase 2 data by the end of this quarter and remain on track to initiate a CUE-401 Phase 1 study by the end of the year.” Business, Financial and Leadership Highlights Milestones CUE-221”
Company press release, Aug 14, 2026 · SEC filing
2H 2026 · “Ascendant-221 is currently being evaluated by Ascendant Health’s related company, Genesis Life Sciences, in a Phase 2 placebo and active comparator-controlled dose-ranging study in chronic spontaneous urticaria (CSU) in China (China Study) with clinical results expected in 2H 2026.”
Company press release, May 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings Reported Q3 2026 net loss of $50.0 million, up from $7.4 million a year earlier, with R&D at $17.0 million and G&A at $29.8 million, largely from non-cash stock compensation. Cash was $57.9 million at September 30, 2026. CUE-401 began first-in-human dosing. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 21, 2026 ·
Clinical trial Reported positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria in a 145-patient China study. At week 12, 54% of the 4 mg/kg group reached complete resolution of hives (HSS7=0) versus 11% on placebo (p<0.005), and 41% on omalizumab was not statistically tested. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Earnings Reported Q2 2026 net loss of $153.1 million, driven by one-time non-cash charges and CUE-221 license costs, with revenue of $7.9 million. Cash fell to $17.4 million at June 30, and a $50 million private placement followed. CUE-221 Phase 2 data is expected by end of Q3 2026. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 12, 2026 ·
Financing Cue Biopharma filed a registration statement to resell up to 1,505,570 shares of common stock, including 87,500 shares issuable on exercise of pre-funded warrants, held by selling stockholders from a July 13, 2026 private placement. The company receives no proceeds except nominal warrant exercise payments. Form S-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2026 · Phase 1 · Results Expected · A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Registry primary completion date, not a results date
Mar 2025 · Phase 1 · Results Expected · A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not CUE's own candidates): Pembrolizumab, WT1-targeted IL-2-based Fusion Protein CUE-102.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CUE holds $17.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $20M/quarter from operations,
an estimated runway of 2.6 months at that rate (BioRadar estimate, not company guidance).
Share count 8,359,523 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CUE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CUE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.